Vanda Puts VQW-765 Anxiety Program on Hold After Phase III Trial Miss

Vanda Pharmaceuticals put its VQW-765 program on hold Oct. 14 after a Phase III trial missed its primary endpoint, which assessed distress scores among women with social anxiety disorder. The secondary analysis of all participants also found no significant difference between the drug and placebo. Study 3201 randomized 546 adults ages 18 to 65 at about 30 U.S. sites to receive one oral dose of VQW-765 or placebo before a public-speaking stress test. The primary endpoint used the 0-to-100 Subjective Units of Distress Scale (SUDS).

Source: TokenPost